Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Age-Related Macular Degeneration

95 clinical trials

86 products

2 drugs

Clinical trial
A Phase 1 Study of the Safety, Pharmacokinetics, and Exploratory Efficacy of Periocular Administration of AIV007 in Subjects With Macular Edema Secondary to Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Status: Recruiting, Estimated PCD: 2025-02-06
Product
Faricimab
Clinical trial
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (AVONELLE-X)
Status: Active (not recruiting), Estimated PCD: 2024-08-09
Clinical trial
Extension Study to Evaluate the Long-term Outcomes of Subjects Following CLS-AX Administration for Age-related Macular Degeneration in the CLS-AX CLS1002-101 Study
Status: Completed, Estimated PCD: 2023-01-05
Product
AIV007
Product
CLS-AX
Clinical trial
A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB15 (Proposed Aflibercept Biosimilar) and Eylea® in Subjects With Neovascular Age-related Macular Degeneration
Status: Completed, Estimated PCD: 2021-04-15
Product
SB15
Product
Eylea
Clinical trial
A Phase I/IIa, Dose-escalation and Dose-extension Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
Status: Recruiting, Estimated PCD: 2027-12-31
Product
ADVM-022
Clinical trial
A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]
Status: Active (not recruiting), Estimated PCD: 2028-08-01
Clinical trial
A Phase 2, Randomized Controlled, Open-Label Study to Establish the Safety and Efficacy of LX102 in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
Status: Recruiting, Estimated PCD: 2025-05-01
Product
Aflibercept
Product
LX102
Product
RRG001
Clinical trial
An Open-label, Single Group, Single-dose Clinical Study to Evaluate the Usability of the Pre-filled Syringe of SB11 in Subjects With Neovascular Age-Related Macular Degeneration or Macular Oedema Secondary to Retinal Vein Occlusion
Status: Completed, Estimated PCD: 2023-11-30
Product
SB11
Clinical trial
An Open-label, Dose-escalation Phase I/IIa Study to Evaluate the Safety and Efficacy of EXG102-031 Intraocular Injection in Participants With Neovascular Age-related Macular Degeneration（wAMD）
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 3, Randomized, Double-masked, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravitreal IBI302(Efdamrofusp Alfa) in Subjects With Neovascular Age-Related Macular Degeneration
Status: Recruiting, Estimated PCD: 2027-02-28
Product
IBI302
Clinical trial
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 2A Randomized Open-Label Controlled Trial to Assess the Safety of Zimura™ (Anti-C5 Aptamer) Administered in Combination With Anti-VEGF Therapy in Treatment Experienced Patients With Neovascular Age-Related Macular Degeneration
Status: Terminated, Estimated PCD: 2018-04-24
Product
OPT-302
Product
Zimura
Product
Avastin
Clinical trial
A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Multi-center, Randomized, Double-masked, Active-controlled Study to Evaluate the Longer Interval of Intravitreal (IVT) Injection of IBI302 in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Product
Lucentis
Clinical trial
A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Status: Not yet recruiting, Estimated PCD: 2024-07-01
Product
MB-102
Product
Fluorescein sodium
Product
OTX-TKI/Sham
Clinical trial
A Prospective Multicenter, Double-Masked, Randomized, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Status: Completed, Estimated PCD: 2023-02-06
Product
Aflibercept/Sham
Product
EXG102-031
Product
MB-102 and Zeiss FF450
Product
Ranibizumab
Product
Avacincaptad Pegol
Product
Sham
Clinical trial
A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI333 in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Status: Active (not recruiting), Estimated PCD: 2023-12-07
Clinical trial
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Completed, Estimated PCD: 2022-07-25
Product
IBI333
Clinical trial
A Phase 2/3 Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Status: Completed, Estimated PCD: 2019-09-26
Clinical trial
FOCUS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects With Macular Atrophy Due to AMD
Status: Active (not recruiting), Estimated PCD: 2024-06-28
Product
GT005
Clinical trial
A Phase IIIb, Multicenter, Randomized, Visual Assessor-Masked Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
Status: Withdrawn, Estimated PCD: 2025-01-31
Clinical trial
A 52-week Multicenter, Randomized, Double-masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea®, Administered Intravitreally, in Patients With Neovascular Age-related Macular Degeneration
Status: Completed, Estimated PCD: 2022-07-07
Clinical trial
A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)
Status: Terminated, Estimated PCD: 2022-10-27
Product
Sham Control
Product
Galegenimab
Product
SOK583A1
Product
Eylea EU
Product
Fluorescein sodium and Zeiss FF450 fundus camera
Clinical trial
A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered Via Subretinal Delivery in Participants With Neovascular Age-related Macular Degeneration
Status: Completed, Estimated PCD: 2023-10-02
Product
RGX-314
Clinical trial
Randomized, Double-blind, Parallel, Active Controlled Study to Compare Efficacy & Safety Between Ranibizumab 10mg/ml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Aflibercept, Compared With Aflibercept Alone, in Participants With nAMD
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Product
OTX-TKI
Clinical trial
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Status: Recruiting, Estimated PCD: 2026-04-29
Clinical trial
Real-World, Long-Term Data Collection to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER STUDY)
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Port Delivery System with Ranibizumab
Product
AVD-104
Product
Avacincaptad
Clinical trial
Evaluation of the Safety and Tolerability of OLX10212 in Patients With Neovascular Age-Related Macular Degeneration
Status: Recruiting, Estimated PCD: 2024-11-01
Product
OLX10212
Clinical trial
A Single and Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Treatment Effect of Intravitreal AVD-104 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Brolucizumab
Clinical trial
A 56-week Phase IIIb/IV, Open-label, One-arm Extension Study to Assess the Efficacy and Safety of Brolucizumab 6 mg in a Treat-to-Control Regimen With Maximum Treatment Intervals up to 20 Weeks for the Treatment of Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
Status: Completed, Estimated PCD: 2023-03-28
Product
Eyecyte-RPE™
Clinical trial
A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Status: Not yet recruiting, Estimated PCD: 2024-10-01
Product
brolucizumab
Clinical trial
A Twelve-Month, Randomized, Double-Masked, Multicenter, Phase III, Two-Arm Study Comparing the Efficacy and Safety of Brolucizumab 6 mg Versus Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
Status: Completed, Estimated PCD: 2024-02-28
Clinical trial
One Year, Single Arm, Open Label, Multicenter, Phase IV Study Using Multimodal Imaging to Guide Disease Activity Assessment Through Innovative Early Predictive Anatomical Biomarkers of Fluid Resolution in wAMD Patients Treated With Brolucizumab- IMAGINE Study
Status: Completed, Estimated PCD: 2023-10-04
Clinical trial
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Status: Active (not recruiting), Estimated PCD: 2022-07-27
Product
Fluorescein sodium + Zeiss FF450
Product
SKG0106
Clinical trial
Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Status: Recruiting, Estimated PCD: 2026-01-01
Product
MB-102 and Zeiss FF450 fundus camera
Product
Aflibercept High Dose VEGF Trap-Eye
Product
Aflibercept VEGF Trap-Eye
Product
Zifibancimig
Clinical trial
A Three-Part, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery From the Port Delivery in Patients With Neovascular Age-Related Macular Degeneration
Status: Recruiting, Estimated PCD: 2026-02-09
Product
Fluorescein sodium + Zeiss FF450 fundus camera
Clinical trial
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impairment Due to Retinal Disorders, NORSE SEVEN
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
bevacizumab
Clinical trial
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)
Status: Recruiting, Estimated PCD: 2026-12-31
Product
PDS Implant with Ranibizumab
Clinical trial
An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration
Status: Completed, Estimated PCD: 2022-06-22
Product
SYL1801
Clinical trial
Eylea Post Marketing Surveillance
Status: Completed, Estimated PCD: 2018-12-31
Product
AR-13503
Clinical trial
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) and Subjects With Diabetic Macular Edema (DME)
Status: Completed, Estimated PCD: 2022-05-12
Clinical trial
A Phase III, Multicenter, Randomized, Two-armed, Double-blind, Parallel, Active-controlled, Non-inferiority Clinical Trial to Compare Efficacy and Safety of Aflibercept (CinnaGen Co, Iran) to the Reference Aflibercept Product (Eylea®, Regeneron, USA) in Patients With Neovascular Age-related Macular Degeneration.
Status: Completed, Estimated PCD: 2022-07-31
Product
TAB014 Monoclonal Antibody
Clinical trial
A Phase III, Randomized, Multicenter, Doubled-blind Clinical Trial Comparing the Efficacy and Safety of TAB014 and Lucentis in Neovascular Age-related Macular Degeneration (nAMD) Patients
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular AMD
Status: Recruiting, Estimated PCD: 2023-07-22
Product
BI 754132
Clinical trial
Safety, Tolerability and Pharmacokinetics of Single Rising Intravitreal Doses and Multiple Intravitreal Dosing of BI 754132 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration (Open Label, Non-randomized, Uncontrolled).
Status: Terminated, Estimated PCD: 2022-08-09
Product
Rabinizumab
Clinical trial
A Long-term Study of ADVM-022 in Neovascular (Wet) AMD - OPTIC Extension
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
Mydriacyl
Clinical trial
A Single Centre, Controlled, Investigation to Evaluate the Performance of the Hyperspectral Camera for Retinal Non-invasive Examination Through the Observation of Retinal Oxygenation
Status: , Estimated PCD: 2023-11-01
Clinical trial
A Phase IIIb, Open-Label, Single-Arm Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the 6-mg Faricimab Prefilled Syringe
Status: Completed, Estimated PCD: 2022-11-10
Product
FYB203
Clinical trial
A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
Status: Completed, Estimated PCD: 2022-06-23
Product
Ivt. Aflibercept
Product
D-4517.2
Clinical trial
A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 (Hydroxyl Dendrimer VEGFR Tyrosine Kinase Inhibitor) After Subcutaneous Administration in Healthy Volunteers
Status: Completed, Estimated PCD: 2022-08-31
Clinical trial
A Phase I/IIa (Phase 1/Phase 2a), Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)
Status: Completed, Estimated PCD: 2019-11-24
Clinical trial
Intravitreal Aflibercept in Neovascular Age-related Macular Degeneration (nAMD): an Observational Study Assessing Patient Relevant Outcomes, Real-world Treatment Pattern and Effectiveness
Status: Completed, Estimated PCD: 2023-03-06
Product
FT-003
Clinical trial
A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity Between SCD411 and Eylea® in Subjects With Neovascular Age-related Macular Degeneration
Status: Completed, Estimated PCD: 2022-09-08
Clinical trial
An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FT-003 in Subjects With Neovascular Age-related Macular Degeneration
Status: Not yet recruiting, Estimated PCD: 2024-11-30
Product
QA108
Product
QA108 granules
Clinical trial
A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular Degeneration
Status: Completed, Estimated PCD: 2021-08-19
Product
Placebo
Product
IONIS-FB-LRx
Clinical trial
A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Prospective, Multi-Center, Open-label, Sequential, Multiple Ascending-Dose and High Concentration Cohorts Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AM712 Following Intravitreal Administration in Patients With Neovascular Age-related Macular Degeneration.
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Two Stage Phase 2 Study: Stage 1: Single Subcutaneous Dose Open-label Assessment of Safety and Pharmacodynamic Response to D-4517.2 (Hydroxyl Dendrimer VEGFR Tyrosine Kinase Inhibitor) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Subjects With Diabetic Macular Edema (DME)
Status: Recruiting, Estimated PCD: 2023-05-31
Product
AM712(ASKG712)
Product
AKST4290
Product
ASKG712
Clinical trial
A Multi-Center, Open-label, Single Ascending-Dose and Multiple Ascending-Dose Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASKG712 Following Intravitreal Administration in Patients With Neovascular Age-related Macular Degeneration
Status: Recruiting, Estimated PCD: 2023-12-31
Product
UBX1325
Clinical trial
A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (Wet AMD)
Status: Completed, Estimated PCD: 2023-02-15
Clinical trial
A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase II Clinical Study of the Efficacy and Safety of QA108 Granules in the Treatment of Intermediate Age-Related Macular Degeneration
Status: Recruiting, Estimated PCD: 2024-03-30
Clinical trial
A Multicenter, Open-label, Multiple Dose Study in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
Status: Terminated, Estimated PCD: 2022-02-18
Clinical trial
OASIS: Open-label, Dose-escalation, Phase 1/2a Study of the Safety and Tolerability of Suprachoroidally Administered CLS-AX Following Intravitreal Anti-VEGF Therapy in Subjects With Neovascular Age-related Macular Degeneration
Status: Completed, Estimated PCD: 2022-10-13
Product
GEM103
Product
SCD411
Product
Anti-VEGF
Clinical trial
A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration
Status: Completed, Estimated PCD: 2021-05-11
Product
Beovu
Product
MHU650
Clinical trial
A Multi-center, Open-Label, Phase 1, Single- and Multiple Ascending Dose Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration (nAMD).
Status: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
A First-in-human, Open-label, Single Ascending Dose Study to Assess Safety and Tolerability of Intravitreal MHU650 in Participants With Macular Edema From Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (nAMD), or Retinal Vein Occlusion (RVO)
Status: Completed, Estimated PCD: 2022-05-24
Clinical trial
ODYSSEY: A Phase 2b Study of Suprachoroidally Administered CLS-AX in Participants With Neovascular Age-Related Macular Degeneration
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 3 Clinical Trial of Intravitreal Injections of Human Recombinant Vascular Endothelial Growth Factor Receptor-Fc Fusion Protein in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status: Completed, Estimated PCD: 2012-12-01
Product
PMC-403
Clinical trial
A Multicenter, Multiple-Dose Study in Neovascular Age-related Macular Degeneration (nAMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, Immunogenicity, and Clinical Effect of Repeat Intravitreal (IVT) Injections of GEM103 as an Adjunct to Standard of Care Aflibercept Therapy
Status: Terminated, Estimated PCD: 2022-01-10
Product
Recombinant Human VEGF Receptor-Fc Fusion Protein
Product
RTH258/Brolucizumab
Clinical trial
Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
Status: Completed, Estimated PCD: 2020-05-22
Clinical trial
A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab (6mg) in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Status: Completed, Estimated PCD: 2022-11-10
Clinical trial
A One-year, Single-arm, Open-label, Multicenter Study Assessing the Effect of Brolucizumab on Disease Control in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration (SWIFT)
Status: Completed, Estimated PCD: 2022-10-05
Clinical trial
Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES)
Status: Completed, Estimated PCD: 2019-04-26
Clinical trial
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography (OCT) Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
Status: Completed, Estimated PCD: 2023-06-28
Product
aflibercept
Product
ranibizumab
Clinical trial
A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants With Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy
Status: , Estimated PCD: 2028-12-01
Clinical trial
Special Drug Use Investigation of EYLEA for AMD
Status: Completed, Estimated PCD: 2018-12-31
Clinical trial
A Dose Escalation Study to Evaluate the Safety and Tolerability of IBI302 Intravitreal Injection in Subjects With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema AND A Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With Diabetic Macular Edema
Status: , Estimated PCD: 2023-10-31
Clinical trial
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Status: Terminated, Estimated PCD: 2022-11-14
Clinical trial
Short-term Results With Faricimab After Multiple Sequential Treatment Switches Due to Resistance With Both Aflibercept and Ranibizumab in Neovascular Age-related Macular Degeneration
Status: Completed, Estimated PCD: 2024-01-15
Clinical trial
China Faricimab Real World Evidence: Evaluation of Faricimab Effectiveness, Safety and Treatment Pattern, in Diabetic Macular Edema, Retinal Vein Occlusion and Neovascular Age-Related Macular Degeneration: The Farseeing Study
Status: Recruiting, Estimated PCD: 2027-11-30
Clinical trial
Anatomical and Visual Outcomes Following a Single Injection of Intravitreal Faricimab in Patients With Neovascular Age-related Macular Degeneration and Persisting Fluid Despite Frequent Aflibercept Treatments
Status: Completed, Estimated PCD: 2023-11-15
Clinical trial
Vitrectomy, Subretinal Tissue Plasminogen Activator and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative Age-Related Macular Degeneration (TIGER): a Phase 3, Pan-European, Two-group, Observer-masked, Superiority, Randomised Controlled Surgical Trial.
Status: Recruiting, Estimated PCD: 2025-01-01
Product
recombinant TPA (Alteplase)
Product
Intravitreal 20% sulfahexafluoride (SF6) gas tamponade
Clinical trial
An Open-label, Dose-escalation Study to Evaluate the Safety, Preliminary Efficacy, Immunogenicity and Pharmacokinetic Characteristics of SKG0106 Intraocular Solution After Single Intravitreal Injection in Chinese Patients With Neovascular (Wet) Age-related Macular Degeneration
Status: Recruiting, Estimated PCD: 2025-05-30
Clinical trial
Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (The Z-AMD Study): A Randomized Controlled Pilot Study
Status: Completed, Estimated PCD: 2024-01-24
Product
Zoledronic Acid
Product
Placebos
Clinical trial
Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration: a Monocenter, Randomized, Double-masked Comparator-controlled Study (FAN)
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Phase 1/2a Study of the Safety and Bioactivity of AXT107 Injected Suprachoroidally in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Product
AXT107
Clinical trial
A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (the DRAW Study)
Status: Completed, Estimated PCD: 2016-12-14
Clinical trial
METforMIN: Metformin Administration for the Minimization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration
Status: Completed, Estimated PCD: 2022-04-01
Drug
Metformin
Clinical trial
The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Bevacizumab
Clinical trial
Clinical and Genetic Analyzes of Age-related Macular Degeneration
Status: Recruiting, Estimated PCD: 2024-11-01
Product
Sampling
Clinical trial
Randomized Controlled Study of Cooled Versus Room-Temperature Artificial Tears for Reducing Surface Irritation Following Intravitreal Injection
Status: Completed, Estimated PCD: 2022-07-01
Product
Refresh Plus
Clinical trial
Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT
Status: Recruiting, Estimated PCD: 2024-09-01
Drug
bevacizumab
Clinical trial
An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Status: Active (not recruiting), Estimated PCD: 2023-06-01
Product
LX102-C01
Clinical trial
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Status: Recruiting, Estimated PCD: 2027-07-30